Synopsis
Synopsis
0
CEP/COS
0
NDC API
0
VMF
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6 Alpha-methylprednisolone Sodium Hemisuccinate
2. A-methapred
3. Hemisuccinate, Methylprednisolone
4. Methylprednisolone Hemisuccinate
5. Methylprednisolone Hemisuccinate Monosodium Salt
6. Methylprednisolone Sodium Hemisuccinate
7. Methylprednisolone Sodium Succinate
8. Methylprednisolone Succinate
9. Sodium Hemisuccinate, Methylprednisolone
10. Sodium Succinate, Methylprednisolone
11. Solumedrol
12. Succinate, Methylprednisolone
13. Urbason-soluble
14. Urbasonsoluble
1. Solu-medrone
2. Urbason Solubile
3. M-6-p
4. Nsc-48989
5. Methylprednisolone Sodium Hemisuccinate
6. U 9088
7. Urabason
8. 2375-03-3
9. Nsc48989
10. Prednisolone, Succinate, Sodium Salt
11. 6.alpha.-methylprednisolone Sodium Succinate
12. 6.alpha.-methylprednisolone 21-sodium Succinate
13. 6.alpha.-methylprednisolone Sodium Hemisuccinate
14. 6.alpha.-methylpregnisolone 21-sodium Succinate
15. 6.alpha.-methylprednisolone 21-sodium Hemisuccinate
16. 6.alpha.-methylprednisolone 21-hemisuccinate Sodium Salt
17. Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-, 21-(hydrogen Succinate), Monosodium Salt
18. Pregna-1,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-, Monosodium Salt, (6.alpha.,11.beta.)-
Molecular Weight | 497.5 g/mol |
---|---|
Molecular Formula | C26H34NaO8+ |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 497.21513732 g/mol |
Monoisotopic Mass | 497.21513732 g/mol |
Topological Polar Surface Area | 138 Ų |
Heavy Atom Count | 35 |
Formal Charge | 1 |
Complexity | 981 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Methylprednisolone sodium succinate |
Drug Label | SOLU-MEDROL Sterile Powder is an antiflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs... |
Active Ingredient | Methylprednisolone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 40mg base/vial; eq 125mg base/vial; eq 500mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Mustafa Nevsat; Fresenius Kabi Usa |
2 of 2 | |
---|---|
Drug Name | Methylprednisolone sodium succinate |
Drug Label | SOLU-MEDROL Sterile Powder is an antiflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs... |
Active Ingredient | Methylprednisolone sodium succinate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 40mg base/vial; eq 125mg base/vial; eq 500mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Mustafa Nevsat; Fresenius Kabi Usa |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Methylprednisolone Sodium Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methylprednisolone Sodium Succinate, including repackagers and relabelers. The FDA regulates Methylprednisolone Sodium Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methylprednisolone Sodium Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Methylprednisolone Sodium Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Methylprednisolone Sodium Succinate supplier is an individual or a company that provides Methylprednisolone Sodium Succinate active pharmaceutical ingredient (API) or Methylprednisolone Sodium Succinate finished formulations upon request. The Methylprednisolone Sodium Succinate suppliers may include Methylprednisolone Sodium Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Methylprednisolone Sodium Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Methylprednisolone Sodium Succinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Methylprednisolone Sodium Succinate active pharmaceutical ingredient (API) in detail. Different forms of Methylprednisolone Sodium Succinate DMFs exist exist since differing nations have different regulations, such as Methylprednisolone Sodium Succinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Methylprednisolone Sodium Succinate DMF submitted to regulatory agencies in the US is known as a USDMF. Methylprednisolone Sodium Succinate USDMF includes data on Methylprednisolone Sodium Succinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Methylprednisolone Sodium Succinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Methylprednisolone Sodium Succinate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Methylprednisolone Sodium Succinate Drug Master File in Japan (Methylprednisolone Sodium Succinate JDMF) empowers Methylprednisolone Sodium Succinate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Methylprednisolone Sodium Succinate JDMF during the approval evaluation for pharmaceutical products. At the time of Methylprednisolone Sodium Succinate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Methylprednisolone Sodium Succinate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Methylprednisolone Sodium Succinate Drug Master File in Korea (Methylprednisolone Sodium Succinate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Methylprednisolone Sodium Succinate. The MFDS reviews the Methylprednisolone Sodium Succinate KDMF as part of the drug registration process and uses the information provided in the Methylprednisolone Sodium Succinate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Methylprednisolone Sodium Succinate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Methylprednisolone Sodium Succinate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Methylprednisolone Sodium Succinate suppliers with KDMF on PharmaCompass.
A Methylprednisolone Sodium Succinate written confirmation (Methylprednisolone Sodium Succinate WC) is an official document issued by a regulatory agency to a Methylprednisolone Sodium Succinate manufacturer, verifying that the manufacturing facility of a Methylprednisolone Sodium Succinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Methylprednisolone Sodium Succinate APIs or Methylprednisolone Sodium Succinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Methylprednisolone Sodium Succinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Methylprednisolone Sodium Succinate suppliers with Written Confirmation (WC) on PharmaCompass.
Methylprednisolone Sodium Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Methylprednisolone Sodium Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methylprednisolone Sodium Succinate GMP manufacturer or Methylprednisolone Sodium Succinate GMP API supplier for your needs.
A Methylprednisolone Sodium Succinate CoA (Certificate of Analysis) is a formal document that attests to Methylprednisolone Sodium Succinate's compliance with Methylprednisolone Sodium Succinate specifications and serves as a tool for batch-level quality control.
Methylprednisolone Sodium Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Methylprednisolone Sodium Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Methylprednisolone Sodium Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Methylprednisolone Sodium Succinate EP), Methylprednisolone Sodium Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methylprednisolone Sodium Succinate USP).
LOOKING FOR A SUPPLIER?